We're thrilled to welcome Scott Turner as the new Chief Scientific Officer at Arda. Scott brings with him a wealth of experience and expertise, particularly in the development and translation of anti-fibrotic therapies. Prior to joining us, Scott served as CSO at Pliant Therapeutics, where he played a pivotal role in the creation of Pliant's fibrosis discovery platform and the development of their anti-fibrotic pipeline. His innovative approaches, including applying single-cell precision cut tissue slice data to dissect drug mechanisms of action and driving an advanced biomarker strategy, led to remarkable successes in achieving clinical proof of concept. With Scott at the helm as our new CSO, we're confident that his expertise will be instrumental in advancing our lead programs towards the clinic and driving innovative approaches to achieve pathogenic cell depletion. Join us in extending a warm welcome to Scott as he embarks on this new journey with Arda! #Leadership #Innovation #CSO #Biotech #Fibrosis
Scott! Big surprise, but a big congrats from me. You've been awesome at your last gig, and I'm looking forward to seeing your impact at the new gig! Let's chat once you get settled in!
Congrats Scott, looks like a great fit. They’re lucky to have you onboard!
Best of luck!
Welcome to the team Scott Turner! Very excited to have you joining us!!!
Wow! Amazing news, Scott and Arda Tx!! What a winning match!
Congratulations, Scott!
Congratulations!
Congratulations Scott Turner and Arda Therapeutics!
Congratulations!
Principal Scientist- Immuno-Oncology Drug Discovery, Pliant Therapeutics
5moCongratulations, Scott. Arda is lucky to have you.